Advanced Synthesis

Built on collaboration and more than 125 years of expertise, our team uses innovative new ways to bring your molecule to life, from the very moment of discovery through to final treatments. Your molecule is our number one priority.

Through our advanced expertise, Lonza entered the bioconjugates market in 2006 with a focus on ADCs. Our portfolio has further extended beyond cytotoxic payload Bioconjugates to include novel non-cytotoxic bioconjugates. We are your integrated, end-to-end CDMO partner to develop and manufacture Bioconjugates.

We offer integrated solutions across all Lonza platforms and modalities. With our world-class, global, high-quality facilities and expertise, we are the only CMDO partner you need.